一小时的血葡萄糖预测了从正常的葡萄糖耐受性到糖尿病前期的进展
Muhammad Abdul-Ghani1, Mohamed Abu-Farha2, Tamam Abdul-Ghani1
1Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Diabetes care
|May 16, 2025
概括
在口服葡萄糖耐受性测试期间血葡萄糖水平升高1小时,预测了糖尿病前期风险. 一小时的葡萄糖水平为120 mg/dL,可以识别患糖尿病前期风险较高的人.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 糖尿病研究 糖尿病研究
背景情况:
- 糖尿病前期是2型糖尿病的重要危险因素.
- 早期识别患有糖尿病前期风险的个体对于及时干预至关重要.
- 口服葡萄糖耐受性测试 (OGTT) 是葡萄糖代谢障碍的标准诊断工具.
研究的目的:
- 评估OGTT的1小时血葡萄糖 (PG) 水平对正常葡萄糖耐受性 (NGT) 个体糖尿病前期发展的预测能力.
- 确定特定的1小时PG值,表明糖尿病前期风险增加.
- 为了表征具有中等1小时PG水平的个体,他们进展到糖尿病前期.
主要方法:
- 分析了圣安东尼奥心脏研究的1557名参与者的数据.
- 基线和重复的OGTT在7.5年的随访期内进行.
- 美国糖尿病协会的标准被用来定义糖尿病前期的发展.
主要成果:
- 24.7%的NGT参与者在7.5年内发展为糖尿病前期.
- 1小时的PG是糖尿病前期发展的最强有力的预测因素.
- 120 mg/dL的1小时PG切点显示 61%的灵敏度和 67%的特异性用于识别高风险个体.
- 患有1小时PG120-155mg/dL且进展的个体表现出严重的胰岛素抵抗和代谢综合征特征.
结论:
- 在OGTT期间增加1小时的PG度,先于糖尿病前期的发展.
- 一个1小时的PG120-155毫克/分升识别了个体在糖尿病前期的风险较高.
- 为这种高风险人群提出了"前糖尿病"一词,因为他们存在恶化葡萄糖耐受性的重大风险.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
488
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
488
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Glucose Homeostasis: Regulation of Blood Glucose
1.3K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140


